Oct 16 (Reuters) - Abbott Laboratories ... newly launched over-the-counter device Lingo, rose nearly 21% organically to more than $1.6 billion. The company's medical devices unit generated ...

Abbott bumps up profit forecast on strong medical device sales The World Health Organization ... son developed after the hospital fed him the companies' formulas. Jury urged to hold formula ...

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

Abbott Laboratories beat third-quarter ... the midpoint of its profit outlook on strong demand for its medical devices. The company posted third-quarter earnings per share (EPS) of 94 cents ...

Abbott announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures.

(Reuters) -Abbott Laboratories slightly ... and newly launched over-the-counter device Lingo, were $1.6 billion, up nearly 21 ...

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7. ...

How Did Abbott Fare In Q3? Abbott’s revenue of $10.6 billion in Q3 was up 4.9% y-o-y. The company reported an 11.7% jump in medical device segment sales, and a 2.7% growth in its established ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as Abbott's popular FreeStyle Libre. The company's CGM ...